An anti-inflammatory composition

Abstract

The present application relates to an anti-inflammatory composition. Specifically, the present application provides a composition comprising a Paris extract and / or a Tricholoma extract. The Paris extract and the Tricholoma extract of the present application have excellent anti-inflammatory effects, and the Paris extract and the Tricholoma extract have synergistic effects in terms of anti-inflammation.

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical technology, and more specifically to an anti-inflammatory composition. Background Technology

[0002] Inflammation is a common disease, and many factors, such as ultraviolet radiation, can lead to inflammation, including dermatitis. During inflammation, the levels of inflammatory factors, such as interleukin-6, often increase. If inflammation is not effectively treated, it can cause various adverse reactions. Common symptoms of dermatitis include erythema, itching, redness and swelling, fever, mild hyperplasia of skin lesions, lichenification, and pigmentation, thus negatively impacting the body. Therefore, effective prevention and treatment of inflammation, such as reducing inflammatory factor levels, has always been a key focus in clinical practice. However, current technology lacks a method that can effectively prevent and treat inflammation, making the development of an effective anti-inflammatory method a current research hotspot.

[0003] Therefore, there is a need in this field to develop an anti-inflammatory method. Summary of the Invention

[0004] The object of this invention is to provide a composition for anti-inflammatory purposes.

[0005] A first aspect of the present invention provides a composition comprising Paris polyphylla extract and / or Matsutake mushroom extract.

[0006] Preferably, the composition comprises Paris polyphylla extract and matsutake mushroom extract.

[0007] Preferably, the extract comprises a dry extract.

[0008] Preferably, the extract includes an extract.

[0009] Preferably, the weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:10-800, more preferably 1:10-500, even more preferably 1:20-400, even more preferably 1:30-300, even more preferably 1:60-260, even more preferably 1:80-240, even more preferably 1:100-220, even more preferably 1:120-200, even more preferably 1:130-190, even more preferably 1:140-180, even more preferably 1:145-175, even more preferably 1:150-170, even more preferably 1:155-165, even more preferably 1:160.

[0010] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0011] (1) Extract Paris polyphylla with an aqueous ethanol solution to obtain an extract. The extract is then extracted with petroleum ether, and the separated aqueous layer is extracted with ethyl acetate. The separated aqueous layer is then extracted with n-butanol to obtain an n-butanol layer extract. The n-butanol layer extract is then evaporated to dryness to obtain Paris polyphylla extract.

[0012] Preferably, in step (1), the volume fraction of ethanol in the aqueous ethanol solution is 30-90%, more preferably 50-90%, more preferably 60-80%, more preferably 65-75%, more preferably 68-72%, and most preferably 70%.

[0013] Preferably, in step (1), the ethanol-water solution is extracted by heating and reflux extraction.

[0014] Preferably, in step (1), Paris polyphylla is extracted with an ethanol aqueous solution and then filtered to obtain an extract.

[0015] Preferably, in step (1), the extraction time of Paris polyphylla by the ethanol aqueous solution is 0.5-5h, more preferably 1-3h, more preferably 1-2h, more preferably 1.3-1.7h, and most preferably 1.5h.

[0016] Preferably, in step (1), the weight ratio of the Paris polyphylla raw material to the ethanol aqueous solution is 1:3-12, more preferably 1:3-10, more preferably 1:4-8, more preferably 1:5-7, more preferably 1:5.5-6.5, and most preferably 1:6.

[0017] Preferably, in step (1), the extract is concentrated and then extracted with petroleum ether.

[0018] Preferably, the concentration includes vacuum concentration.

[0019] Preferably, the concentration temperature is 20-90°C, more preferably 30-80°C, even more preferably 40-70°C, even more preferably 50-70°C, even more preferably 55-65°C, even more preferably 58-62°C, and most preferably 60°C.

[0020] Preferably, the concentration includes vacuum concentration at 40-70°C (more preferably 50-70°C, even more preferably 55-65°C, even more preferably 58-62°C, most preferably 60°C).

[0021] Preferably, the concentration factor is 3-10 times, more preferably 4-8 times, even more preferably 5-7 times, even more preferably 5.5-6.5 times, and most preferably 6 times.

[0022] Preferably, in step (1), the volume ratio of the concentrated extract to the aqueous ethanol solution is 1:3-12, more preferably 1:3-10, even more preferably 1:4-8, more preferably 1:5-7, more preferably 1:5.5-6.5, and most preferably 1:6.

[0023] Preferably, in step (1), the volume ratio of petroleum ether to the extract is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0024] Preferably, in step (1), the volume ratio of the petroleum ether to the concentrated extract is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0025] Preferably, in step (1), the volume ratio of ethyl acetate to the aqueous layer separated by petroleum ether extraction is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0026] Preferably, in step (1), the volume ratio of n-butanol to the aqueous layer separated by ethyl acetate extraction is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0027] Preferably, the evaporation is performed by vacuum concentration evaporation.

[0028] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0029] (1) Add Paris polyphylla to a 65-75% (v / v) ethanol aqueous solution, heat and reflux to extract, and then add petroleum ether to the extract for extraction. The separated aqueous layer is extracted with ethyl acetate, and then the separated aqueous layer is extracted with n-butanol to obtain the n-butanol layer extract. The n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract.

[0030] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0031] (1) Add Paris polyphylla to a 65-75% (v / v) ethanol aqueous solution, heat and reflux to extract, filter, concentrate the filtrate under reduced pressure, add petroleum ether to the concentrate for extraction, extract the separated aqueous layer with ethyl acetate, then extract the separated aqueous layer with n-butanol to obtain the n-butanol layer extract, concentrate the n-butanol layer extract under reduced pressure and evaporate to dryness to obtain Paris polyphylla extract.

[0032] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0033] (1) Add Paris polyphylla to a 65-75% (v / v) ethanol aqueous solution, heat and reflux for 1-2 hours, filter, concentrate the filtrate under reduced pressure, add petroleum ether to the concentrate for extraction, extract the separated aqueous layer with ethyl acetate, then extract the separated aqueous layer with n-butanol, and separate the n-butanol layer extract. The n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract.

[0034] Preferably, in step (1), the volume ratio of the concentrate to the aqueous ethanol solution is 1:3-12, more preferably 1:3-10, even more preferably 1:4-8, more preferably 1:5-7, more preferably 1:5.5-6.5, and most preferably 1:6.

[0035] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0036] (1) Add Paris polyphylla to a 70% (v / v) aqueous ethanol solution, heat and reflux to extract, and then add petroleum ether to the extract for extraction. The separated aqueous layer is extracted with ethyl acetate, and then the separated aqueous layer is extracted with n-butanol to obtain the n-butanol layer extract. The n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract.

[0037] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0038] (1) Take 200g of Paris polyphylla, add 1200mL of 70% (v / v) ethanol aqueous solution, heat and reflux for 1.5h, filter, concentrate the filtrate under reduced pressure at 60℃ to obtain 200mL of concentrate, add an equal volume of petroleum ether to the concentrate for extraction, extract the separated aqueous layer with an equal volume of ethyl acetate, and then extract the separated aqueous layer with an equal volume of n-butanol to obtain the n-butanol layer extract, concentrate the n-butanol layer extract under reduced pressure at 60℃ to dryness to obtain Paris polyphylla extract.

[0039] Preferably, the matsutake mushroom extract is prepared by the following method, the method comprising:

[0040] (a) Matsutake mushrooms were extracted with water to obtain an extract. Ethanol was added to the extract, the mixture was allowed to stand, and then filtered to obtain matsutake mushroom extract.

[0041] Preferably, in step (a), the method of extracting matsutake mushrooms with water includes decoction extraction.

[0042] Preferably, in step (a), the matsutake mushroom is extracted with water and then filtered to obtain an extract.

[0043] Preferably, in step (a), the temperature at which water extracts matsutake mushrooms is 20-100℃, more preferably 30-100℃, even more preferably 40-100℃, even more preferably 50-100℃, even more preferably 60-100℃, even more preferably 70-100℃, even more preferably 80-100℃, even more preferably 90-100℃, even more preferably 95-100℃, and most preferably 100℃.

[0044] Preferably, in step (a), the extraction time of matsutake mushrooms with water is 0.5-5h, more preferably 1-3h, even more preferably 1.5-2.5h, even more preferably 1.8-2.2h, and most preferably 2h.

[0045] Preferably, in step (a), the weight ratio of the matsutake mushroom raw material to the water is 1:5-30, more preferably 1:5-20, even more preferably 1:5-15, even more preferably 1:8-12, even more preferably 1:9-11, even more preferably 1:9.5-10.5, even more preferably 1:9.8-10.2, and most preferably 1:10.

[0046] Preferably, in step (a), ethanol is added to the extract while stirring.

[0047] Preferably, in step (a), the extract is concentrated before ethanol is added.

[0048] Preferably, the concentration includes vacuum concentration.

[0049] Preferably, the concentration factor is 3-20 times, more preferably 5-15 times, even more preferably 8-12 times, even more preferably 9-11 times, even more preferably 9.5-10.5 times, even more preferably 9.8-10.2 times, and most preferably 10 times.

[0050] Preferably, in step (a), the volume ratio of the concentrated extract to the water is 1:3-20, more preferably 1:5-15, even more preferably 1:8-12, even more preferably 1:9-11, even more preferably 1:9.5-10.5, even more preferably 1:9.8-10.2, and most preferably 1:10.

[0051] Preferably, in step (a), the volume ratio of ethanol to the extract is 1:0.3-8, more preferably 1:0.5-5, even more preferably 1:0.5-4, even more preferably 1:1-3, more preferably 1:1.5-2.5, more preferably 1:1.8-2.2, and most preferably 1:2.

[0052] Preferably, in step (a), the volume ratio of ethanol to the concentrated extract is 1:0.3-8, more preferably 1:0.5-5, even more preferably 1:0.5-4, even more preferably 1:1-3, more preferably 1:1.5-2.5, more preferably 1:1.8-2.2, and most preferably 1:2.

[0053] Preferably, in step (a), ethanol is added to the concentrated extract while stirring.

[0054] Preferably, in step (a), the settling temperature is 2-8°C, more preferably 2-6°C, even more preferably 3-5°C, even more preferably 3.5-4.5°C, and most preferably 4°C.

[0055] Preferably, in step (a), the settling time is 2-12h, more preferably 3-10h, more preferably 4-8h, more preferably 5-7h, more preferably 5.5-6.5h, more preferably 5.8-6.2h, and most preferably 6h.

[0056] Preferably, in step (a), the matsutake mushroom extract is obtained by centrifugation and then filtration after standing.

[0057] Preferably, in step (a), the centrifugation speed is 4000-12000 r / min, more preferably 6000-10000 r / min, even more preferably 7000-9000 r / min, even more preferably 7500-8500 r / min, even more preferably 7800-8200 r / min, and most preferably 8000 r / min.

[0058] Preferably, in step (a), the centrifugation time is 3-15 min, more preferably 3-10 min, even more preferably 3-8 min, even more preferably 4-6 min, even more preferably 4.5-5.5 min, and most preferably 5 min.

[0059] Preferably, in step (a), the filtered precipitate is the matsutake mushroom extract.

[0060] Preferably, the precipitate is dried to obtain matsutake mushroom extract.

[0061] Preferably, the matsutake mushroom extract is prepared by the following method, the method comprising:

[0062] (a) Matsutake mushrooms are extracted with water, filtered to obtain an extract, the extract is concentrated under reduced pressure to obtain a concentrate, ethanol is added to the concentrate, the mixture is allowed to stand, centrifuged, and filtered to obtain matsutake mushroom extract.

[0063] Preferably, the volume ratio of ethanol to the concentrate is 1:0.3-8, more preferably 1:0.5-5, even more preferably 1:0.5-4, even more preferably 1:1-3, more preferably 1:1.5-2.5, more preferably 1:1.8-2.2, and most preferably 1:2.

[0064] Preferably, the matsutake mushroom extract is prepared by the following method, the method comprising:

[0065] (a) Matsutake mushrooms are boiled in water to extract the extract, filtered to obtain an extract, and the extract is concentrated under reduced pressure to obtain a concentrate. 0.3-0.7 times the amount of ethanol is added to the concentrate, and the mixture is allowed to stand at 2-6°C for 4-8 hours. After centrifugation, the extract is filtered to obtain matsutake mushroom extract.

[0066] Preferably, the matsutake mushroom extract is prepared by the following method, the method comprising:

[0067] Take 200g of matsutake mushrooms, add 2000mL of water, decoct at 100℃ for 2h, filter, concentrate the filtrate under reduced pressure to obtain 200mL of concentrate, then add 0.5 times the volume of ethanol to the concentrate while stirring, let stand at 4℃ for 6h, centrifuge at 8000r / min for 5min, filter to obtain precipitate, and dry the precipitate to obtain matsutake mushroom extract.

[0068] Preferably, the content of the Paris polyphylla extract is 0.001-99.9 wt%, more preferably 0.1-99 wt%, more preferably 1-99 wt%, more preferably 1-90 wt%, more preferably 10-90 wt%, more preferably 20-80 wt%, more preferably 30-70 wt%, more preferably 20-40 wt%, based on the weight of the composition.

[0069] Preferably, the content of the matsutake extract is 0.001-99.9 wt%, more preferably 0.1-99 wt%, even more preferably 1-99 wt%, even more preferably 1-90 wt%, even more preferably 10-90 wt%, even more preferably 20-80 wt%, even more preferably 30-70 wt%, even more preferably 20-40 wt%, based on the weight of the composition.

[0070] Preferably, the composition comprises an anti-inflammatory composition.

[0071] Preferably, the composition is a pharmaceutical composition, a food composition, a health product composition, or a cosmetic composition.

[0072] Preferably, the composition further includes a pharmaceutically, food-grade, health product-grade, or cosmetically acceptable carrier.

[0073] Preferably, the dosage form of the composition is a solid dosage form, a semi-solid dosage form, or a liquid dosage form.

[0074] Preferably, the dosage form of the pharmaceutical composition, food composition, or health product composition is an oral preparation.

[0075] Preferably, the dosage form of the pharmaceutical composition or cosmetic composition is a topical preparation.

[0076] Preferably, the dosage form of the pharmaceutical composition or cosmetic composition is a cream, lotion, solution, spray, or patch.

[0077] Preferably, the composition is administered to a human being.

[0078] A second aspect of the present invention provides an active ingredient combination, the active ingredient combination comprising the following components:

[0079] (i) a first active ingredient, said first active ingredient comprising Paris polyphylla extract; and / or

[0080] (ii) A second active ingredient, wherein the second active ingredient includes matsutake mushroom extract.

[0081] Preferably, the Paris polyphylla extract is as described in the first aspect of the present invention.

[0082] Preferably, the matsutake mushroom extract is as described in the first aspect of the present invention.

[0083] Preferably, the combination of active ingredients includes a combination of anti-inflammatory active ingredients.

[0084] Preferably, the weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:10-800, more preferably 1:10-500, even more preferably 1:20-400, even more preferably 1:30-300, even more preferably 1:60-260, even more preferably 1:80-240, even more preferably 1:100-220, even more preferably 1:120-200, even more preferably 1:130-190, even more preferably 1:140-180, even more preferably 1:145-175, even more preferably 1:150-170, even more preferably 1:155-165, even more preferably 1:160.

[0085] Preferably, in the combination of active ingredients, at least one active ingredient is independent.

[0086] Preferably, in the combination of active ingredients, the first active ingredient and the second active ingredient are independent of each other.

[0087] A third aspect of the present invention provides a medicine box, food box, health product box, or cosmetic box, wherein the medicine box, food box, health product box, or cosmetic box comprises:

[0088] (A) A first formulation containing a first active ingredient, said first active ingredient comprising Paris polyphylla extract; and / or

[0089] (B) A second formulation containing a second active ingredient, said second active ingredient including matsutake mushroom extract.

[0090] Preferably, the Paris polyphylla extract is as described in the first aspect of the present invention.

[0091] Preferably, the matsutake mushroom extract is as described in the first aspect of the present invention.

[0092] Preferably, the medicine box, food box, health product box, or cosmetic box includes anti-inflammatory medicine box, food box, health product box, or cosmetic box.

[0093] Preferably, the weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:10-800, more preferably 1:10-500, even more preferably 1:20-400, even more preferably 1:30-300, even more preferably 1:60-260, even more preferably 1:80-240, even more preferably 1:100-220, even more preferably 1:120-200, even more preferably 1:130-190, even more preferably 1:140-180, even more preferably 1:145-175, even more preferably 1:150-170, even more preferably 1:155-165, even more preferably 1:160.

[0094] Preferably, the first and second formulations are independent formulations.

[0095] Preferably, the first and second formulations are combined formulations.

[0096] Preferably, the medicine box, food box, health product box, or cosmetic box also includes an instruction manual.

[0097] Preferably, the instructions for use specify that the first preparation and the second preparation are used in combination for anti-inflammatory purposes.

[0098] The fourth aspect of the present invention provides the use of a composition as described in the first aspect of the present invention, an active ingredient combination as described in the second aspect of the present invention, or a medicine box, food box, health product box, or cosmetic box as described in the third aspect of the present invention, for the preparation of a drug, food, health product, or cosmetic, wherein the drug, food, health product, or cosmetic is used for one or more uses selected from the group consisting of: (i) reducing the level of inflammatory factors; and / or (ii) anti-inflammatory.

[0099] Preferably, the anti-inflammatory measures include prevention and / or treatment of inflammation.

[0100] Preferably, the inflammation includes skin inflammation.

[0101] Preferably, the inflammation includes human inflammation.

[0102] Preferably, the anti-inflammatory target includes humans.

[0103] Preferably, the skin includes human skin.

[0104] Preferably, the inflammation includes inflammation caused by light radiation.

[0105] Preferably, the light radiation includes ultraviolet radiation.

[0106] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0107] Preferably, the area radiated by the light includes the skin.

[0108] Preferably, the inflammation includes inflammation caused by an increase in inflammatory factors.

[0109] Preferably, the inflammation includes inflammation caused by an increase in inflammatory factors due to light radiation.

[0110] Preferably, the anti-inflammatory effect includes reducing the level of inflammatory factors to reduce inflammation.

[0111] Preferably, the level includes a content level.

[0112] Preferably, the inflammatory factors include inflammatory factors in cells.

[0113] Preferably, the inflammatory factors in the cells are elevated.

[0114] Preferably, the inflammatory factor includes interleukin-6.

[0115] Preferably, the cells include light-radiated cells.

[0116] Preferably, the cells include cells that elevate inflammatory factors due to light radiation.

[0117] Preferably, the cells include skin cells.

[0118] Preferably, the cells include keratinocytes and / or epidermal cells.

[0119] Preferably, the cells comprise HaCaT cells.

[0120] Preferably, the drug, food, health product, or cosmetic is applied to humans.

[0121] Preferably, the dosage form of the drug, food, health product or cosmetic is a solid dosage form, a semi-solid dosage form or a liquid dosage form.

[0122] Preferably, the dosage form of the drug, food, or health product is an oral preparation.

[0123] Preferably, the dosage form of the drug or cosmetic is a topical preparation.

[0124] Preferably, the dosage form of the drug or cosmetic is a cream, lotion, solution, spray, or patch.

[0125] The fifth aspect of the present invention provides a method for reducing the level of cellular inflammatory factors, the method comprising the steps of:

[0126] Contacting cells with a composition as described in the first aspect of the invention or a combination of active ingredients as described in the second aspect of the invention reduces the level of cellular inflammatory factors.

[0127] Preferably, the cells include human cells.

[0128] Preferably, the cells include skin cells.

[0129] Preferably, the cells include keratinocytes and / or epidermal cells.

[0130] Preferably, the cells comprise HaCaT cells.

[0131] Preferably, the inflammatory factors in the cells are elevated.

[0132] Preferably, the inflammatory factor includes interleukin-6.

[0133] Preferably, the cells include light-radiated cells.

[0134] Preferably, the light radiation includes ultraviolet radiation.

[0135] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0136] Preferably, the cells include cells that elevate inflammatory factors due to light radiation.

[0137] Preferably, the method includes non-therapeutic and non-diagnostic methods.

[0138] Preferably, the method includes an in vitro method.

[0139] Preferably, the contact includes external contact.

[0140] Preferably, the contact includes contact in an in vitro culture medium.

[0141] The sixth aspect of the present invention provides a method for reducing inflammatory factor levels and / or reducing inflammation, the method comprising administering to a desired subject a composition as described in the first aspect of the present invention, a combination of active ingredients as described in the second aspect of the present invention, or a medicine box, food box, health product box, or cosmetic box as described in the third aspect of the present invention, thereby reducing inflammatory factor levels and / or reducing inflammation.

[0142] Preferably, the object includes a person.

[0143] Preferably, the anti-inflammatory measures include prevention and / or treatment of inflammation.

[0144] Preferably, the inflammation includes skin inflammation.

[0145] Preferably, the inflammation includes human inflammation.

[0146] Preferably, the anti-inflammatory target includes humans.

[0147] Preferably, the skin includes human skin.

[0148] Preferably, the inflammation includes inflammation caused by light radiation.

[0149] Preferably, the light radiation includes ultraviolet radiation.

[0150] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0151] Preferably, the area radiated by the light includes the skin.

[0152] Preferably, the inflammation includes inflammation caused by an increase in inflammatory factors.

[0153] Preferably, the inflammation includes inflammation caused by an increase in inflammatory factors due to light radiation.

[0154] Preferably, the anti-inflammatory effect includes reducing the level of inflammatory factors to reduce inflammation.

[0155] Preferably, the level includes a content level.

[0156] Preferably, the inflammatory factors include inflammatory factors in cells.

[0157] Preferably, the inflammatory factors in the cells are elevated.

[0158] Preferably, the inflammatory factor includes interleukin-6.

[0159] Preferably, the cells include light-radiated cells.

[0160] Preferably, the cells include cells that elevate inflammatory factors due to light radiation.

[0161] Preferably, the cells include skin cells.

[0162] Preferably, the cells include keratinocytes and / or epidermal cells.

[0163] Preferably, the cells comprise HaCaT cells.

[0164] Preferably, the application includes oral or topical application.

[0165] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Attached Figure Description

[0166] Figure 1 The value represents the IL-6 (interleukin-6) content in the cell lysis supernatant after treatment in each group, where p represents whether there is a significant difference compared with the model group, "*" indicates p < 0.05, "**" indicates p < 0.01, and "***" indicates p < 0.001. Detailed Implementation

[0167] This invention develops a Paris polyphylla extract and a matsutake mushroom extract, which have excellent anti-inflammatory effects. Furthermore, experimental studies of this invention show that specific amounts of Paris polyphylla extract and matsutake mushroom extract have excellent synergistic effects in anti-inflammatory aspects.

[0168] the term

[0169] As used herein, the terms “comprising,” “including,” and “containing” are used interchangeably and include not only open-ended definitions but also semi-closed and closed definitions. The terms include “consisting of” and “substantially consisting of”.

[0170] In this invention, the term "Paris fargesii Franch." refers to the dried rhizome of the herb *Paris fargesii* Franch.

[0171] As used in this article, the term "matsutake" refers to the fruiting body of the fungus *Tricholoma matsutake* (S. Ito & S. Imai) Singer, belonging to the family Tricholomataceae.

[0172] As used herein, the term “70% (v / v) aqueous ethanol solution” refers to an aqueous solution of ethanol with a volume fraction of 70%, for example, “70% (v / v) aqueous ethanol solution is prepared by mixing 70 mL of anhydrous ethanol and 30 mL of water, and so on.”

[0173] As used in this article, the terms “anti-inflammatory” and “anti-inflammatory treatment” are used interchangeably.

[0174] As used in this article, the term "IL-6" refers to interleukin-6.

[0175] As used in this article, the term "DMEM medium" refers to Dulbecco's Modified Eagle Medium.

[0176] As used in this article, the term "ELISA" refers to enzyme-linked immunosorbent assay.

[0177] In this invention, the term "prevention" means a method of preventing the onset of a disease and / or its accompanying symptoms or protecting a subject from acquiring a disease.

[0178] In this invention, the term "treatment" includes delaying and stopping the progression of a disease, or eliminating the disease, without requiring 100% inhibition, eradication, and reversal.

[0179] Paris polyphylla extract

[0180] This invention provides a Paris polyphylla extract, which has excellent anti-inflammatory effects.

[0181] In a preferred embodiment of the present invention, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0182] (1) Extract Paris polyphylla with an aqueous ethanol solution to obtain an extract. The extract is then extracted with petroleum ether, and the separated aqueous layer is extracted with ethyl acetate. The separated aqueous layer is then extracted with n-butanol to obtain an n-butanol layer extract. The n-butanol layer extract is then evaporated to dryness to obtain Paris polyphylla extract.

[0183] Specifically, the Paris polyphylla extract described in this invention is as described in the first aspect of this invention above.

[0184] Matsutake mushroom extract

[0185] This invention provides a matsutake mushroom extract, which has excellent anti-inflammatory effects.

[0186] In a preferred embodiment of the present invention, the matsutake mushroom extract is prepared by the following method, the method comprising:

[0187] (a) Matsutake mushrooms were extracted with water to obtain an extract. Ethanol was added to the extract, the mixture was allowed to stand, and then filtered to obtain matsutake mushroom extract.

[0188] Specifically, the matsutake mushroom extract of this invention is as described in the first aspect of this invention above.

[0189] use

[0190] The Paris polyphylla extract and Matsutake mushroom extract described in this invention have excellent anti-inflammatory effects, and the Paris polyphylla extract and Matsutake mushroom extract described in this invention have excellent synergistic effects in anti-inflammatory aspects.

[0191] Composition

[0192] The present invention also provides a composition, preferably a pharmaceutical composition, a food composition, a health product composition, or a cosmetic composition. The composition of the present invention further includes a pharmaceutically, food-, health product-, or cosmetically acceptable carrier.

[0193] As used herein, the term "pharmaceutical, food, health product or cosmetic acceptable carrier" refers to one or more compatible solid, semi-solid, liquid or gel fillers that are suitable for human or animal use and have sufficient purity and sufficiently low toxicity.

[0194] It should be understood that the carrier described in this invention is not particularly limited and can be any material commonly used in the art, prepared by conventional methods, or purchased from the market. Acceptable examples of carriers include cellulose and its derivatives (such as methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, etc.), polyols (such as propylene glycol, glycerin, sorbitol, etc.), emulsifiers (such as Tween), wetting agents (such as sodium dodecyl sulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal absorption promoters, colorants, flavoring agents, stabilizers, antioxidants, preservatives, antibacterial agents, pyrogen-free water, etc.

[0195] In a preferred embodiment of the present invention, the composition of the present invention comprises Paris polyphylla extract and Matsutake mushroom extract.

[0196] In a preferred embodiment of the present invention, the weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:10-800, more preferably 1:10-500, more preferably 1:20-400, more preferably 1:30-300, more preferably 1:60-260, more preferably 1:80-240, more preferably 1:100-220, more preferably 1:120-200, more preferably 1:130-190, more preferably 1:140-180, more preferably 1:145-175, more preferably 1:150-170, more preferably 1:155-165, and more preferably 1:160.

[0197] In this invention, the dosage form of the composition includes (but is not limited to) solid dosage forms, semi-solid dosage forms, or liquid dosage forms.

[0198] Pharmaceutical formulations should be matched with the route of administration, which involves administering a therapeutically effective amount of the drug to the intended recipient (e.g., a human or non-human mammal). As used herein, the term "therapeutically effective amount" refers to an amount that is functionally or activityily produced in humans and / or animals and is acceptable to them. Those skilled in the art will understand that the "therapeutically effective amount" can vary depending on the form of the pharmaceutical formulation, the route of administration, the excipients used, the severity of the disease, and whether it is used in combination with other drugs, all of which are within the scope of the skill of a skilled physician.

[0199] The main technical effects achieved by this invention include:

[0200] This invention develops a Paris polyphylla extract and a matsutake mushroom extract, which have excellent anti-inflammatory effects (such as anti-skin inflammation) and exhibit excellent synergistic effects in anti-inflammatory aspects.

[0201] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that the following specific embodiments are based on the present technical solution and provide detailed implementation methods and specific operation processes, but the scope of protection of the present invention is not limited to these embodiments.

[0202] Example 1

[0203] This embodiment examines the anti-inflammatory effects of different Chinese herbal extracts and their combinations.

[0204] 1. Preparation of different Chinese herbal extracts

[0205] 1.1 Preparation of Paris polyphylla extract

[0206] (1) Take 200g of crushed Paris polyphylla, add 1200mL of 70% (v / v) ethanol aqueous solution, heat and reflux for 1.5h, filter, concentrate the filtrate under reduced pressure at 60℃ to obtain 200mL concentrate, add an equal volume of petroleum ether to the concentrate for extraction, extract the separated aqueous layer with an equal volume of ethyl acetate, and then extract the separated aqueous layer with an equal volume of n-butanol to obtain the n-butanol layer extract, concentrate the n-butanol layer extract under reduced pressure at 60℃ to dryness to obtain Paris polyphylla extract.

[0207] 1.2 Preparation of Matsutake Extract

[0208] Take 200g of crushed matsutake mushrooms, add 2000mL of water, decoct at 100℃ for 2h, filter, concentrate the filtrate under reduced pressure to obtain 200mL of concentrate, then add 0.5 times the volume of ethanol to the concentrate while stirring, let stand at 4℃ for 6h, centrifuge at 8000r / min for 5min, filter to obtain precipitate, and dry the precipitate to obtain matsutake mushroom extract.

[0209] 2. Investigation on the anti-inflammatory effects of different Chinese herbal extracts and their combinations

[0210] DMEM medium: DMEM basal medium + 10% FBS + 1% penicillin-streptomycin solution.

[0211] 2.1 Experimental Methods and Results

[0212] The experiment included a control group, a model group, experimental group A, experimental group B, and experimental group C. HaCaT cells (human immortalized keratinocytes) in the logarithmic growth phase were collected from each group at a concentration of 2 × 10⁻⁶ cells / mL. 6 Cells were seeded at a density of cells / mL onto multi-well cell culture plates, with 1 mL of cell suspension added to each well. The plates were incubated overnight at 37°C and 5% CO2, then the culture medium was discarded. Finally, 1 mL of the following drug was added to each well for treatment:

[0213] Control group: DMEM medium;

[0214] Model group: DMEM medium;

[0215] Experimental group A: DMEM medium dispersion of Paris polyphylla extract, wherein the concentration of Paris polyphylla extract is 5 μg / mL;

[0216] Experimental group B: DMEM medium dispersion of matsutake extract, wherein the concentration of matsutake extract was 0.8 mg / mL;

[0217] Experimental group C: DMEM medium dispersion of Paris polyphylla extract and matsutake mushroom extract, wherein the concentration of Paris polyphylla extract was 5 μg / mL and the concentration of matsutake mushroom extract was 0.8 mg / mL;

[0218] Each group was repeated three times. After drug administration, each group was incubated at 37°C and 5% CO2 for 6 hours. Then, except for the control group, all other groups were subjected to the same UVA ultraviolet radiation (9 J / cm²). 2 After UV radiation treatment, each group was cultured for another 24 hours. Then, the culture medium was removed from each well, and the cells were washed with PBS 7.4 buffer. 400 μL of cell lysis buffer (prepared at a RIPA:PMSF ratio of 100:1) was added to each well to lyse the cells. The cells were then centrifuged at 10000 rpm at 4°C for 5 minutes, and the supernatant was collected. The total protein content in the cell lysis supernatant was determined using the BCA (Bicinchoninic acid) method, and the IL-6 (interleukin-6) content in the cell lysis supernatant was detected using an ELISA kit (Cloud-Clone Crop). The IL-6 (interleukin-6) content in the cell lysis supernatant of each group is shown below. Figure 1 As shown in Table 1.

[0219] Table 1. IL-6 (interleukin-6) content in cell lysate supernatant after treatment in each group (M±SD)

[0220]

[0221] Note: Except for the control group, all other groups were stimulated with the same UVA ultraviolet light (9J / cm²). 2 ).

[0222] from Figure 1 As shown in Table 1, compared with the model group, the Paris polyphylla extract and Matsutake mushroom extract of Example 1 effectively reduced the content of the inflammatory factor IL-6, thus exhibiting excellent anti-inflammatory effects. Specifically, compared with the reduction of IL-6 content by Paris polyphylla extract and Matsutake mushroom extract alone in experimental groups A and B, the combined use of specific amounts of Paris polyphylla extract and Matsutake mushroom extract in experimental group C showed a synergistic effect in reducing IL-6 content. Therefore, the combined use of specific amounts of Paris polyphylla extract and Matsutake mushroom extract in experimental group C had a synergistic effect in anti-inflammation, thereby significantly improving the anti-inflammatory effect.

[0223] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. An anti-inflammatory composition, characterized in that, The anti-inflammatory composition is made from Paris polyphylla extract and Matsutake mushroom extract; The Paris polyphylla extract is prepared by the following method, which includes: (1) Extract the Paris polyphylla with an aqueous ethanol solution to obtain an extract. The extract is then extracted with petroleum ether, and the separated aqueous layer is extracted with ethyl acetate. The separated aqueous layer is then extracted with n-butanol to obtain an n-butanol layer extract. The n-butanol layer extract is then evaporated to dryness to obtain the Paris polyphylla extract. The matsutake mushroom extract is prepared by the following method, which includes: (a) Matsutake mushrooms were extracted with water to obtain an extract. Ethanol was added to the extract, the mixture was allowed to stand, and then filtered to obtain matsutake mushroom extract. In step (1), the volume fraction of ethanol in the aqueous ethanol solution is 65-75%. The weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:150-170.

2. The anti-inflammatory composition according to claim 1, characterized in that, The weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:

160.

3. The anti-inflammatory composition according to claim 1, characterized in that, In step (1), the volume fraction of ethanol in the aqueous ethanol solution is 70%; and In step (a), the temperature for standing is 2-6°C.

4. The anti-inflammatory composition according to claim 1, characterized in that, The Paris polyphylla extract is prepared by the following method, which includes: (1) Add Paris polyphylla to a 65-75% v / v ethanol aqueous solution, heat and reflux to extract, and extract the extract. Add petroleum ether to the extract for extraction. Extract the separated aqueous layer with ethyl acetate. Then extract the separated aqueous layer with n-butanol to obtain the n-butanol layer extract. The n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract. The matsutake mushroom extract is prepared by the following method, which includes: (a) Matsutake mushrooms are boiled in water to extract the extract, filtered to obtain an extract, the extract is concentrated under reduced pressure to obtain a concentrate, 0.3-0.7 times the amount of ethanol is added to the concentrate, the mixture is allowed to stand at 2-6℃ for 4-8 hours, centrifuged, and filtered to obtain matsutake mushroom extract.

5. The anti-inflammatory composition according to claim 1, characterized in that, The anti-inflammatory composition is a pharmaceutical composition or a cosmetic composition.

6. The anti-inflammatory composition according to claim 1, characterized in that, The anti-inflammatory composition also includes a pharmaceutically or cosmetically acceptable carrier.

7. The anti-inflammatory composition according to claim 1, characterized in that, The anti-inflammatory composition is in the form of a solid dosage form, a semi-solid dosage form, or a liquid dosage form.

8. A combination of active ingredients for anti-inflammatory purposes, characterized in that, The aforementioned anti-inflammatory active ingredient combination consists of the following components: (i) a first active ingredient, wherein the first active ingredient is Paris polyphylla extract; and (ii) A second active ingredient, wherein the second active ingredient is matsutake mushroom extract; The Paris polyphylla extract is prepared by the following method, which includes: (1) Extract the Paris polyphylla with an aqueous ethanol solution to obtain an extract. The extract is then extracted with petroleum ether, and the separated aqueous layer is extracted with ethyl acetate. The separated aqueous layer is then extracted with n-butanol to obtain an n-butanol layer extract. The n-butanol layer extract is then evaporated to dryness to obtain the Paris polyphylla extract. The matsutake mushroom extract is prepared by the following method, which includes: (a) Matsutake mushrooms were extracted with water to obtain an extract. Ethanol was added to the extract, the mixture was allowed to stand, and then filtered to obtain matsutake mushroom extract. In step (1), the volume fraction of ethanol in the aqueous ethanol solution is 65-75%. The weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:150-170.

9. The combination of active ingredients for anti-inflammatory purposes as described in claim 8, characterized in that, The weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:

160.

10. A reagent kit for anti-inflammatory purposes, characterized in that, The active ingredient in the anti-inflammatory kit consists of the following components: (A) A first formulation of a first active ingredient, wherein the first active ingredient is a Paris polyphylla extract; and (B) A second formulation of the second active ingredient, wherein the second active ingredient is matsutake mushroom extract; The Paris polyphylla extract is prepared by the following method, which includes: (1) Extract the Paris polyphylla with an aqueous ethanol solution to obtain an extract. The extract is then extracted with petroleum ether, and the separated aqueous layer is extracted with ethyl acetate. The separated aqueous layer is then extracted with n-butanol to obtain an n-butanol layer extract. The n-butanol layer extract is then evaporated to dryness to obtain the Paris polyphylla extract. The matsutake mushroom extract is prepared by the following method, which includes: (a) Matsutake mushrooms were extracted with water to obtain an extract. Ethanol was added to the extract, the mixture was allowed to stand, and then filtered to obtain matsutake mushroom extract. In step (1), the volume fraction of ethanol in the aqueous ethanol solution is 65-75%. The weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:150-170.

11. The anti-inflammatory kit as described in claim 10, characterized in that, The weight ratio of the Paris polyphylla extract to the Matsutake mushroom extract is 1:

160.

12. The anti-inflammatory kit as described in claim 10, characterized in that, The first and second formulations are independent formulations; or The first and second formulations are combined formulations.

13. Use of an anti-inflammatory composition as claimed in claim 1, an anti-inflammatory active ingredient combination as claimed in claim 8, or an anti-inflammatory kit as claimed in claim 10, characterized in that, Used in the preparation of drugs or cosmetics for anti-inflammatory purposes.

14. The use as described in claim 13, characterized in that, The inflammation mentioned includes inflammation of the human skin.

15. The use as described in claim 13, characterized in that, The inflammation mentioned includes inflammation caused by ultraviolet radiation.

16. The use as described in claim 13, characterized in that, The dosage form of the drug or cosmetic is a solid dosage form, a semi-solid dosage form, or a liquid dosage form.

Images